Abstract :

Medications with a narrow therapeutic index (NTI), such as phenytoin, warfarin, and vancomycin, require precise dosing to avoid adverse effects and ensure they remain effective. This is particularly important for at-risk groups like elderly individuals or those with multiple health conditions. The therapeutic index (TI) is a key measurement that indicates the range between a drug’s therapeutic and toxic levels. NTI drugs need careful management because even small changes in their concentration can lead to significant risks and impact their therapeutic benefits. Factors unique to each patient, such as age, existing health conditions, and genetic differences, can affect how NTI drugs are metabolized and their overall effectiveness. As a result, therapeutic drug monitoring (TDM) is crucial for tailoring dosing strategies and minimizing the risk of harm. Interactions between NTI drugs and other medications, especially those that involve cytochrome P450 enzymes, can influence drug concentrations, making treatment more complex. The growing field of personalized medicine, which includes pharmacogenomics, aims to improve outcomes by customizing drug therapies based on individual genetic characteristics. Proper management of NTI drugs requires teamwork among healthcare professionals, including doctors, pharmacists, and nurses. Continued research, along with advancements in drug delivery systems and artificial intelligence, holds potential to enhance the safety and effectiveness of NTI medications.

---

Keywords :

Carbamazepine, Heparin., NTI drugs, Phenytoin, Therapeutic index, Vancomycin, Warfarin

---

References :

1. Sam Habet, Narrow Therapeutic Index drugs: clinical pharmacology perspective, Journal of Pharmacy and Pharmacology, Volume 73, Issue 10, October 2021, Pages 1285–1291,DOI: https://doi.org/10.1093/jpp/rgab102
2. Mark Donnelly, Lanyan Fang, Rajanikanth Madabushi. Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations. 11 November 2024.DOI:https://doi.org/10.1002/cpt.3460.
3. Burns, M. Management of Narrow Therapeutic Index Drugs. J Thromb Thrombolysis7, 137–143 (1999). DOI: https://doi.org/10.1023/A:1008829403320
4. Sam Habet. Narrow Therapeutic Index (NTI) Drugs: Definitions and Criteria. January 04, 2023. 10.22541/au.167285903.32760018/v1
5. McKenzie LE, Kimberlin, CL, Pendergrast JF, Berado, DH. Potential drug interventions in a highrisk ambulatory elderly population. J Geriat Drug Ther1994;8137:49–63.
6. Pivdiro AS. Managing medication in the elderly. Hosp Direct1995;59–64
7. PhD Leslie M. Shaw, PhD David W. Holt, MD Paul Keown et.al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Accepted 16 August 1999, Available online 27 January 2000.DOI : https://doi.org/10.1016/S0149-2918(99)80044-7
8. Bryan A. Liang MD, PhD, JD, Tim K. Mackey MAS, Kimberly M. Lovett MD. Illegal “No Prescription” Internet Access to Narrow Therapeutic Index Drugs. Accepted 28 March 2013, Available online 15 April 2013.DOI: https://doi.org/10.1016/j.clinthera.2013.03.019
9. Tamargo, J., Le Heuzey, JY. & Mabo, P. Narrow therapeutic index drugs: a clinical pharmacological consideration to fecainide. Eur J Clin Pharmacol71, 549–567 (2015). DOI: https://doi.org/10.1007/s00228-015-1832-0
10. Muller, P., Milton, M. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov11, 751–761 (2012).DOI:  https://doi.org/10.1038/nrd3801
11. Blix HS, Viktil KK, Moger TA, Reikvam A. Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Granada). 2010 Jan;8(1):50-5. doi: 10.4321/s1886-36552010000100006. Epub 2010 Mar 15. PMID: 25152793; PMCID: PMC4140577.
12. Mervyn J. Eadie. First published: 02 October 2015. DOI: https://doi.org/10.1002/9781118936979.ch43
13. Ambrósio, A.F., Soares-da-Silva, P., Carvalho, C.M. et al.Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 27, 121–130 (2002). DOI:  https://doi.org/10.1023/A:1014814924965
14. Raymund Machovich. Mechanism of action of heparin through thrombin on blood coagulation. Volume 412, Issue 1, 18 November 1975. DOI: https://doi.org/10.1016/0005-2795(75)90334-7
15. Hammes WP, Neuhaus FC.1974.On the Mechanism of Action of Vancomycin: Inhibition of Peptidoglycan Synthesis in Gaffkya homari. DOI:https://doi.org/10.1128/aac.6.6.722
16. Jack Hirsh, MD, FCCP ∙ James E. Dalen, MD, FCCP ∙ Daniel Deykin et.al. Oral Anticoagulants Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Volume 108, Issue 4, Supplement 231S-246SOctober 1995. DOI: 1378/chest.108.4_Supplement.231S
17. Prof I Ralph Edwards, FRCP, Jeffrey K Aronson, FRCP. Adverse drug reactions: definitions, diagnosis, and management. Published October 7, 2000. DOI: 1016/S0140-6736(00)02799-9
18. Stephens MDB. Definitions and classifications of adverse reaction terms. In: Stephens MDB, Talbot JCC, Routledge PA, eds. The detection of new adverse reactions, 4th edn. London: Macmillan Reference, 1998: 32–44.
19. Kazunari Yoshida , Hiroyoshi Takeuch. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. 20 January 2021. https://doi.org/10.1016/j.bbr.2020.113098
20. Lappin, G., Noveck, R., & Burt, T. (2013). Microdosing and drug development: past, present and future. Expert Opinion on Drug Metabolism & Toxicology, 9(7), 817–834. https://doi.org/10.1517/17425255.2013.786042
21. Lappin, G. (2010). Microdosing: Current and The Future. Bioanalysis, 2(3), 509–517. https://doi.org/10.4155/bio.09.177
22. I. Geller, N. Shehab, M.C. Lovegrove et.al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations JAMA Intern. Med., 174 (2014), pp. 678-686, 10.1001/jamainternmed.2014.136
23. Agnes Beate Bußmann , Lorenz Maximilian Grünerbel , Claudia Patricia Durasiewicz et.al. Microdosing for drug delivery application—A review. https://doi.org/10.1016/j.sna.2021.112820
24. Stefanie D. Krämer, Bernard Testa. The Biochemistry of Drug Metabolism – An Introduction. First published: 19 October 2009. https://doi.org/10.1002/cbdv.200900233
25. Wynne H. Drug metabolism and ageing. British Menopause Society Journal. 2005;11(2):51-56. doi:10.1258/136218005775544589
26. Muaed Jamal Alomar. Factors affecting the development of adverse drug reactions. https://doi.org/10.1016/j.jsps.2013.02.003
27. Tomlinson JEM, McMahon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma Thorax 2005;60:282-287.
28. Noriko Daneshtalab BSc, Dr Richard Z. Lewanczuk MDal. Rheumatoid Arthritis Does Not Reduce the Pharmacodynamic Response to Valsartan. First published: 08 March 2013.https://doi.org/10.1177/0091270003262951
29. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009 Mar;24(1):1-10. doi: 10.3904/kjim.2009.24.1.1. PMID: 19270474; PMCID: PMC2687654.
30. Sebastian G. Wicha, Anne-Grete Märtson, Elisabet I. Nielsen, Birgit C.P. Koch, Lena E. Fribergal. From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. 10 February 2021. https://doi.org/10.1002/cpt.2202
31. Giovanni Sotgiu, Jan-Willem C. Alffenaar et.al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. 23 March 2015. https://doi.org/10.1016/j.ijid.2014.12.001
32. Dipesh Prajapati. Optimizing Patient Care: A Review on Therapeutic Drug Monitoring of some Clinically used Drugs. 3 No. 04 (2023): International Journal of Pharmaceutical Sciences and Clinical Research. DOI: https://doi.org/10.22377/ijpscr.v3i04.175
33. W. Mapleson. Computation of the effect of Donnan equilibrium on pH in equilibrium dialysis. Journal of Pharmacological Methods Volume 17, Issue 3, May 1987, Pages 231-242. https://doi.org/10.1016/0160-5402(87)90053-2
34. Behrouz Seyfinejad, Sibel A. Ozkan, Abolghasem Jouyban. Recent advances in the determination of unbound concentration and plasma protein binding of drugs: Analytical methods. Talanta Volume 225, 1 April 2021, 122052. https://doi.org/10.1016/j.talanta.2020.122052
35. Charmi Manoj Chhatrala, Bhanu Kumar M and Nikita Pal. Assessment of drug-related problems associated with narrow therapeutic index drugs: A prospective cohort study July 28, 2023 https://doi.org/10.1177/25160435231190192
36. Kapil Iyer1*, Neha Dilipkumar1, Sharmin Vasaya1, Sunita Pawar, Arundhati Diwan. Comparison of Drug Related Problems Associated with Use of Narrow Therapeutic Index Drugs and Other Drugs In Hospitalized Patients 2018; 10(3): 318-321
37. Yasuhiro Masubuchi &Toshiharu Horie. Toxicological Significance of Mechanism Based Inactivation of Cytochrome P450 Enzymes by Drugs 10 Oct 2008 https://doi.org/10.1080/1040844070121523
38. Srinivas Maddi1*, Thirumaleswara Goud2 and Pratima Srivastava1. Cytochrome P450 Enzymes, Drug Transporters and their Role in Pharmacokinetic Drug-Drug Interactions of Xenobiotics: A Comprehensive Review 11 July, 2017 DOI: 10.17352/ojc.000006
39. Yuan Wei1 & Chenxiao Tang1 & Vinayak Sant 1 & Song Li1 &Samuel M. Poloyac 1 & Wen Xie1. A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism 4 May 2016 DOI 10.1007/s40495-016-0062-1
40. Lucia Gozzo 1,2,ORCID,Filippo Caraci 3,4,5 and Filippo. Drago Bioequivalence, Drugs with Narrow Therapeutic Index and the Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution 26 July 2022 https://doi.org/10.3390/healthcare10081392
41. Svein I. Johannessen and Cecilie Johannessen Landmark. Antiepileptic Drug Interactions – Principles and Clinical Implications 01 Sep 2010 https://doi.org/10.2174/157015910792246254
42. Ge Zhang a, Daniel W. Nebert. Personalized medicine: Genetic risk prediction of drug response 14 February 2017, https://doi.org/10.1016/j.pharmthera.2017.02.036
43. Rasmussen, Henrik Berg; Dahmcke, Christina Mackeprang. Genome-wide identification of structural variants in genes encoding drug targets Possible implications for individualized drug therapy July 2012. DOI:10.1097/FPC.0b013e328352c770
44. Grant R. Wilkinson. Drug Metabolism and Variability among Patients in Drug Response May 26, 2005 DOI: 10.1056
45. Rachel J. Tyson Rachel J. Tyson1Christine C. Park Christine C. Park1J. Robert Powell J. Robert Powell1 Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables 22 April 2020 https://doi.org/10.3389/fphar.2020.00420
46. Pauline du Rusquec1,2, Thomas Filleron3, Christophe Le Tourneaun.Drug development in the era of precision medicine in oncology—Clues beyond randomization June 06, 2021 doi: 10.21037/cco-21-29
47. Watkins, Zachary. Beyond Glucose: Breakthroughs in Translating Electrochemical Aptamer Biosensors into Point-of-care and Wearable Platforms for Longitudinal Monitoring of Clinically Relevant Analytes August 03, 2025 http://orcid.org/0000-0002- 4789-1846
48. Waszyk-Nowaczyk M, Guzenda W, Dragun P, Olsztyńska L, Liwarska J, Michalak M, et al. Interdisciplinary Cooperation between Pharmacists and Nurses—Experiences and Expectations. International Journal of Environmental Research and Public Health [Internet]. 2022 Sep 16;19(18):11713.
49. Dilles T, Heczkova J, Tziaferi S, Helgesen AK, Grøndahl VA, Van Rompaey B, et al. Nurses and Pharmaceutical Care: Interprofessional, Evidence-Based Working to Improve Patient Care and Outcomes. International Journal of Environmental Research and Public Health [Internet]. 2021 Jun 2;18(11):5973.
50. Ahlam juwaybir Alanazi1, Fahad hassan saeed alqahtani, Ahmed Nasser Altamimi et.al. The role of pharmacists, nurses, and medical practitioner in medication adherence and personalized medicine. DOI: 10.53555/jptcp.v29i04.5080
51. Presley B, Groot W, Pavlova M. Pharmacists’ and patients’ perceptions about the importance of pharmacist services types to improve medication adherence among patients with diabetes in Indonesia. BMC Health Services Research. 2021 Nov 13;21(1).
52. Eyal Zimlichman, Martine Szyper-Kravitz, Avraham Untermanal. How is my patient doing? Evaluating hospitalized patients using continuous vital signs monitoring. Isr Med Assoc J. 2009 Jun;11(6):382-4. PMID: 19697594
53. De Baetselier E, Dilles T, Batalha LM, Dijkstra NE, Fernandes MI, Filov I, et al. Perspectives of nurses’ role in interprofessional pharmaceutical care across 14 European countries: A qualitative study in pharmacists, physicians and nurses. Schneider CR, editor. PLOS ONE. 2021 May 27;16(5):e0251982.
54. Lucia Gozzo, Filippo Caraci , Filippo Drago. Bioequivalence, Drugs with Narrow Therapeutic Index and the Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution. 2022 Jul 26;10(8):1392. doi: 3390/healthcare10081392
55. Burns M. Management of narrow therapeutic index drugs. Journal of Thrombosis and Thrombolysis. 1999;7(2):137–43.
56. Habet S. Narrow Therapeutic Index drugs: clinical pharmacology perspective. Journal of Pharmacy and Pharmacology. 2021 Aug 4;73(10).
57. Jiang W. FDA Drug Topics: Understanding Generic Narrow Therapeutic Index Drugs [Internet]. Available from: https://www.fda.gov/media/162779/download
58. Ramesh Roshan Yadav, Dr. Yogananda R, B. Shankar Reddy. Narrow therapeutic index drugs-a critical study on prescription trends in south Indian tertiary care hospital. 03 Nov. 2018 DOI: 10.20959/wjpr201819-13691
59. Hege S. Blix, Kirsten K. Viktil, Tron A. Moger, and Aasmund Reikvam. Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Granada). 2010 Jan-Mar; 8(1): 50–55. Published online 2010 Mar 15. doi: 10.4321/s1886-36552010000100006
60. Narrow Therapeutic Index Drugs | DrugBank Online [Internet]. go.drugbank.com. Available from: https://go.drugbank.com/categories/DBCAT003972
61. Physicochemical failure modes for Narrow Therapeutic Index (NTI) drugs [Internet]. European Pharmaceutical Review. 2021 [cited 2025 Jan 27]. Available from: https://www.europeanpharmaceuticalreview.com/article/157918/physicochemical-failure-modes-for-first-line-therapy-narrow-therapeutic-index-nti-drugs-a-call-for-attention-nti-risk-classification-and-new-prior-knowledge/

62. Gentry EP. Empirical evidence of risk penalties for NTI Drugs. Journal of Risk and Uncertainty [Internet]. 2019;58(2/3):219–44.
63. Texas NDP PharmD Clinical Assistant Professor Director, Austin/San Antonio Area Community Pharmacy Residency Program.The University of Texas at Austin College of Pharmacy Austin. Generic Substitution of Narrow Therapeutic Index Drugs [Internet]. www.uspharmacist.com. [cited 2023 Mar 10].